Skip to main content
. 2021 May 4;40(21):3707–3718. doi: 10.1038/s41388-021-01808-3

Fig. 5. Survival association for LRIG1 in melanoma depends on EGFR expression and on molecular subtype.

Fig. 5

Kaplan–Meier estimates based on RNAseq data, mutation status, and observed survival (OBS) data extracted from a TCGA data set on metastasized melanoma patients: A All 299 patients in the metastatic melanoma cohort with sequenced tissue from TCGA was divided into LRIG1 high/low groups based on the median. This cohort was further divided in two sub-cohorts at the median for EGFR tumor tissue expression. The resulting sub-cohorts of patients with (B) low EGFR expression or (C) high EGFR expression were then analyzed based on LRIG1 expression and OBS using Kaplan–Meier estimates. D–G Similarly, using the same dataset, we extracted patient samples with available mutational data (N = 296). We then divided those into molecular subtypes as defined previously [36]: D Patients with activating V600 or K601 mutations in BRAF. E Patients with activating G12, G13, or Q61 mutations in HRAS, KRAS, or NRAS. F Patients with inactivating mutations in NF1. G Triple wild-type patients without any of the above mutations.